Cardiology Medical News about everolimus and zotarolimus eluting stents

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents
European Heart Journal, 07/02/09

Camici GG et al. – Rapamycin increases tissue factor (TF) activity and promotes arterial thrombosis in vivo at concentrations relevant in pts undergoing drug-eluting stents (DES) implantation; this effect may increase the thrombogenicity of DES. Since everolimus and zotarolimus augment endothelial TF expression and activity in vitro in a similar manner as rapamycin, these findings may also be relevant for second generation DES.

Methods

Study of effect of mammalian target of rapamycin (mTOR) inhibition on TF activity and thrombus formation in vivo
Investigation of whether second-generation DES substances everolimus and zotarolimus have an effect on endothelial TF expression
Use of a mouse carotid artery photochemical injury model

Results

In mouse model, rapamycin (182 ± 27.5 µg/L) decreased time to thrombotic occlusion by 40%, increased TF activity, and abrogated p70S6K phosphorylation vs controls
In vitro, rapamycin, everolimus, and zotarolimus (each 10–7 mol/L) enhanced TNF-{alpha}-induced TF expression by 2.2-, 1.7-, and 2.4-fold, respectively, which was paralleled by an increase in TF surface activity
Similar to rapamycin, everolimus and zotarolimus abrogated TNF-{alpha}-induced p70S6K phosphorylation under these conditions

<< Previous
A simplified biventricular defibrillator with fixed long...

Next >>
Usefulness of the SYNTAX score for predicting clinical outcome...

Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: The SPIRIT III 4.0 mm registry
Catheterization and Cardiovascular Interventions, 11/04/09 Relevance Score: 80%%

Abbotts XIENCE PRIME and XIENCE V Receive Indications in Europe for Treatment of Patients with Diabetes
Abbott, 11/03/09 Relevance Score: 80%%

Five-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent
Catheterization and Cardiovascular Interventions, 10/30/09 Relevance Score: 79%%

Comparison of the Efficacy and Safety of Zotarolimus-, Sirolimus-, and Paclitaxel-Eluting Stents in Patients With ST-Elevation Myocardial Infarction
The American Journal of Cardiology, 11/06/09 Relevance Score: 78%%

Clinical Outcomes After Sirolimus-Eluting, Paclitaxel-Eluting, and Bare Metal Stents (from the First Phase of the Prospective Multicenter German DES.DE Registry)
The American Journal of Cardiology, 11/09/09 Relevance Score: 71%%